Table 1. Subgroups analysis of OR and DC achievement in R + PGLD group.
| Characteristics | OR | DCR | |||||
|---|---|---|---|---|---|---|---|
| Yes (n=48) | No (n=26) | P value | Yes (n=66) | No (n=8) | P value | ||
| Age, years | 51.0±11.7 | 52.0±10.4 | 0.707 | 50.8±11.0 | 55.8±12.4 | 0.313 | |
| Gender | 0.760 | 1.000 | |||||
| Female | 8 | 5 | 11 | 2 | |||
| Male | 40 | 21 | 55 | 6 | |||
| HBsAg | 0.195 | 0.339 | |||||
| Positive | 38 | 24 | 54 | 8 | |||
| Negative | 10 | 2 | 12 | 0 | |||
| Cirrhosis | 0.760 | 0.624 | |||||
| Yes | 40 | 21 | 55 | 6 | |||
| No | 8 | 5 | 11 | 2 | |||
| Child-Pugh grade | 0.705 | 1.000 | |||||
| A | 42 | 24 | 59 | 7 | |||
| B | 6 | 2 | 7 | 1 | |||
| Portal vein invasion | <0.001 | 0.021 | |||||
| Yes | 20 | 8 | 28 | 0 | |||
| No | 28 | 18 | 38 | 8 | |||
| Hepatic vein invasion | 0.003 | 0.096 | |||||
| Yes | 19 | 2 | 21 | 0 | |||
| No | 29 | 24 | 45 | 8 | |||
| Largest tumor size | <0.001 | 0.714 | |||||
| <5 cm | 3 | 14 | 34 | 5 | |||
| ≥5 cm | 45 | 12 | 32 | 3 | |||
| Tumor number | 1.000 | 0.185 | |||||
| <2 | 25 | 14 | 17 | 0 | |||
| ≥2 | 23 | 12 | 49 | 8 | |||
| ECOG | 0.431 | 0.688 | |||||
| 0–1 | 32 | 20 | 47 | 5 | |||
| 2 | 16 | 6 | 19 | 3 | |||
| BCLC stage | <0.001 | 0.004 | |||||
| A | 0 | 6 | 6 | 0 | |||
| B | 19 | 14 | 25 | 8 | |||
| C | 29 | 6 | 35 | 0 | |||
| AFP | 0.804 | 1.000 | |||||
| <20 ng/mL | 18 | 11 | 26 | 3 | |||
| ≥20 ng/mL | 30 | 15 | 40 | 5 | |||
| WBC, 109/L | 5.7±2.3 | 6.1±2.5 | 0.475 | 5.8±2.4 | 6.2±2.0 | 0.620 | |
| PLT, 109/L | 132.8±48.6 | 155.1±56.7 | 0.097 | 141.8±54.0 | 131.4±37.1 | 0.496 | |
| ALB, g/L | 44.4±4.8 | 44±5.1 | 0.744 | 44.4±4.9 | 43.8±4.4 | 0.722 | |
| TBIL, µmol/L | 16.7±6.6 | 14.8±6.9 | 0.054 | 15.3±6.3 | 17.1±7.4 | 0.545 | |
| ALT, U/L | 48.9±30.2 | 47.0±26.9 | 0.787 | 47.9±29.0 | 51.1±30.3 | 0.782 | |
| AST, U/L | 49.4±27.4 | 47.0±26.9 | 0.125 | 47.3±27.1 | 37.1±12.7 | 0.087 | |
OR, objective response; DC, disease control; R + PGLD, raltitrexed plus polyethylene glycol liposomal doxorubicin; HBsAg, hepatitis B virus surface antigen; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; WBC, white blood cell; PLT, platelet; ALB, albumin; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase.